Diabetic Macular Edema: Therapeutic Options

Treatment for diabetic macular edema (DME) is continuously evolving with the advent of pharmacologic therapies. Focal laser photocoagulation remains the historical standard of care; however, a new wave of studies is rapidly emerging that shows the benefit of intravitreal antivascular endothelial gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Amol D., Ip, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508119/
https://www.ncbi.nlm.nih.gov/pubmed/22392532
http://dx.doi.org/10.1007/s13300-012-0002-y
_version_ 1782251182612283392
author Kulkarni, Amol D.
Ip, Michael S.
author_facet Kulkarni, Amol D.
Ip, Michael S.
author_sort Kulkarni, Amol D.
collection PubMed
description Treatment for diabetic macular edema (DME) is continuously evolving with the advent of pharmacologic therapies. Focal laser photocoagulation remains the historical standard of care; however, a new wave of studies is rapidly emerging that shows the benefit of intravitreal antivascular endothelial growth factor medications and corticosteroids. The goal of this review is to compare the various treatment options for DME, and include data from the most recent clinical trials of therapies for this complex condition.
format Online
Article
Text
id pubmed-3508119
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Healthcare Communications
record_format MEDLINE/PubMed
spelling pubmed-35081192012-11-28 Diabetic Macular Edema: Therapeutic Options Kulkarni, Amol D. Ip, Michael S. Diabetes Ther Review Treatment for diabetic macular edema (DME) is continuously evolving with the advent of pharmacologic therapies. Focal laser photocoagulation remains the historical standard of care; however, a new wave of studies is rapidly emerging that shows the benefit of intravitreal antivascular endothelial growth factor medications and corticosteroids. The goal of this review is to compare the various treatment options for DME, and include data from the most recent clinical trials of therapies for this complex condition. Springer Healthcare Communications 2012-03-06 2012-12 /pmc/articles/PMC3508119/ /pubmed/22392532 http://dx.doi.org/10.1007/s13300-012-0002-y Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Kulkarni, Amol D.
Ip, Michael S.
Diabetic Macular Edema: Therapeutic Options
title Diabetic Macular Edema: Therapeutic Options
title_full Diabetic Macular Edema: Therapeutic Options
title_fullStr Diabetic Macular Edema: Therapeutic Options
title_full_unstemmed Diabetic Macular Edema: Therapeutic Options
title_short Diabetic Macular Edema: Therapeutic Options
title_sort diabetic macular edema: therapeutic options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508119/
https://www.ncbi.nlm.nih.gov/pubmed/22392532
http://dx.doi.org/10.1007/s13300-012-0002-y
work_keys_str_mv AT kulkarniamold diabeticmacularedematherapeuticoptions
AT ipmichaels diabeticmacularedematherapeuticoptions

Ejemplares similares